Dr. John Cush RheumNow
4 years 1 month ago
TREAT EARLIER Study - Is MTX Intevention in Pre-Clinical RA Warranted?
https://t.co/rGcm1DSwJk https://t.co/paBrJVMXdP
Dr. John Cush RheumNow
4 years 1 month ago
Belimumab (Benlysta) has been FDA approved for use in pediatric patients with active lupus nephritis who are receiving standard lupus therapy. The approval in kids is for the IV formulation only; SC belimumab is for SLE and LN in adults https://t.co/LCUFDpZM6j https://t.co/R2kA2DbxKy
Mehta et al have published a full read review of managing interstitial lung disease (ILD) in patients with inflammatory myopathies, a heterogeneous group of syndromes connected by ILD and and increased morbidity and mortality risk.
They divide myositis-ILD into three main prognostic groups with different treatment approaches:
Dr. John Cush RheumNow
4 years 1 month ago
Metanalysis of cardiovascular effects of Colchicine: 21 RCTs (15,569 pts shows colchicine was superior to placebo reducing CV events; with lower risk recurrent pericarditis (RR 0.50), MACE (RR 0.67), & AFib recurrence (RR 0.68) https://t.co/oQEF7dmkH8 https://t.co/P7IKeZpcUB
Dr. John Cush RheumNow
4 years 1 month ago
Single center, retrospective chart study shows that in 168 PsA patients, 26% were assessed within 6wks of referral. Median wait time = 78.5 d. The most common cause of delay was the lack of available spots in the PsA clinic. https://t.co/FDfFgxHhLD https://t.co/CYoT1PBp8l
Dr. John Cush RheumNow
4 years 1 month ago
No Risk of RA w/ coffee consumption -- Swedish EIRA study, included 2184 early RA pts. High Coffee (>6 cups/day) was assoc w/ increased RA risk (OR 1.50;1.20–1.88) that was lost after adjusting for smoking (OR 1.14;0.89–1.45). https://t.co/3SIeHD4fII https://t.co/NqkjmuzSaV
Fever of unknown origin (FUO) represents a diagnostic challenge to many physicians and while cancer and infectious causes need to be excluded, rheumatic disorders are amongst the most common causes of FUO.
A recent metanalysisi of the medical literature from 2002 to 2021, included studies with ≥50 patients reporting on causes of FUO/IUO (inflammation of unknown origin). This series included 16884 patients.
Dr. John Cush RheumNow
4 years 1 month ago
Nintedinib’s Durable Efficacy in Systemic Sclerosis
Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said.
https://t.co/7rUuB6RRow https://t.co/MqBjOj1myW
Dr. John Cush RheumNow
4 years 1 month ago
Metanalysis of 13 trials of corticosteroids (CS) in hand #OA shows no significant effect of intra-articular CS for CMC1 OA (pain or function); but medium effect of oral CS on pain & stiffness & functional improvement at 4-6 weeks. https://t.co/u30bPuQOOr https://t.co/4Z1ZpiOcvX
There is no “test” (blood or other) that is solely diagnostic of Still’s disease, but labs can help make a diagnosis or manage disease, and affirm the safety of drugs in use.
Dr. John Cush RheumNow
4 years 1 month ago
EMA in Europe has approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who are DMARD-IR or biologic-IR. Based on 3 phase III trials. https://t.co/BjvUm0wPNk https://t.co/IVisAgD1wZ
Dr. John Cush RheumNow
4 years 1 month ago
BSRBR mandates LFTs q3 mos if on MTX. 1011 RA pts during the pandemic had median of 5 blood tests & median interval of 57 days. 61% pts had 1 prolonged interval (99-150d) & 24% had multiple. Cytopenia & ^LFTs were not increased by interval length https://t.co/VqY4qIMvOS https://t.co/HcTcmFBuvq
Dr. John Cush RheumNow
4 years 1 month ago
210 consecutive #RA pts starting #MTX looked at effect of autoantibodies on drug response. DAS28-CRP low dz activity at 6 mos was significantly lower with SSA+ (56% v 76%, P=0.03) - which was more significant than CCP+ or RF+ https://t.co/DoEtldBXi4
Figures https://t.co/yIECjLiEwl
The Johns Hopkins Hospital has repeated its top rank among US Rheumatology centers - ranking #1 for the 18th year in a row, according to U.S. News & World Report’s 2022–23 Best Hospitals list released yesterday.
